On February 4, 2020, BenchSci completed its US$22 million Series B financing round led by F-Prime Capital. The funding will be used to launch new offerings including an AI-assisted reagent selection product, and an expansion of its contract with Novartis.
BenchSci is a technology firm specialized in healthcare technology focused on using biomedical artificial intelligence to help researchers run successful experiments.
F-Prime Capital is an investment firm specialized in investments in healthcare and technology focused growth stage companies.
Osler, Hoskin & Harcourt LLP advised BenchSci with a team consisting of Chad Bayne, Justin Dharamdial and Shalu Atwal (Emerging and High Growth Companies).